Tharimmune Files 8-K: Corporate Updates & Financials

Ticker: CNTN · Form: 8-K · Filed: May 22, 2024 · CIK: 1861657

Tharimmune, INC. 8-K Filing Summary
FieldDetail
CompanyTharimmune, INC. (CNTN)
Form Type8-K
Filed DateMay 22, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: corporate-update, filing, financials

TL;DR

THARIMMUNE files 8-K with corporate updates and financials. Check for deets.

AI Summary

Tharimmune, Inc. filed an 8-K on May 22, 2024, reporting amendments to its Articles of Incorporation or Bylaws, other events, and financial statements/exhibits. The company, formerly known as Hillstream BioPharma Inc., is incorporated in Delaware and headquartered in Bridgewater, NJ.

Why It Matters

This filing provides crucial updates on Tharimmune's corporate structure and financial reporting, which are essential for investors to assess the company's current status and future prospects.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for corporate updates and financial statements, not indicating any immediate operational or financial distress.

Key Players & Entities

FAQ

What specific amendments were made to Tharimmune's Articles of Incorporation or Bylaws?

The filing indicates amendments were made, but the specific details of these amendments are not provided in this summary section of the 8-K.

What are the 'Other Events' reported in this 8-K filing?

The filing lists 'Other Events' as a category, but the specific nature of these events is not detailed in the provided header information.

When was Tharimmune, Inc. formerly known as Hillstream BioPharma Inc.?

The company was formerly known as Hillstream BioPharma Inc. prior to a name change on September 25, 2023.

What is Tharimmune's fiscal year end?

Tharimmune's fiscal year ends on December 31st.

Where are Tharimmune's principal executive offices located?

Tharimmune's principal executive offices are located at 1200 Route 22 East, Suite 2000, Bridgewater, NJ 08807.

Filing Stats: 563 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-05-22 16:15:21

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 22, 2024 Tharimmune, Inc. /s/ Randy Milby Randy Milby Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing